Advice

following a full submission assessed under the end of life process:

nivolumab (Opdivo®) is accepted for use within NHSScotland.

Indication under review: in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).

Overall survival was significantly longer in the nivolumab plus ipilimumab group compared with a multiple receptor tyrosine kinase inhibitor in a phase III study in treatment naïve patients with intermediate/poor-risk advanced RCC.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of nivolumab in combination with ipilimumab.

Medicine details

Medicine name:
nivolumab (Opdivo)
SMC ID:
SMC2153
Indication:
In combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma.
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
10 June 2019